How Did Charlie Mills Make His Money?

Quick answer

Charlie Mills made his money the old-fashioned way: he owned a piece of a great business and helped make it enormous. His father, Jim Mills, co-founded Medline Industries in 1966. Charlie became CEO in 1997, when the company did about $600 million in annual sales. Over the next 26 years, he grew it into a $25.5 billion medical-supply giant — then took it public in December 2025 in a $6.26 billion IPO, the largest in the world that year. Forbes values his stake at $11 billion in 2026.

There was no startup lottery ticket here, no viral product, no overnight flip. It was four decades of compounding — sales growth, reinvestment, and one perfectly timed public listing. For the full fortune breakdown, see Charlie Mills' net worth.

An inheritance that came with homework

Charlie Mills was born Charles N. Mills in 1961 in Chicago, Illinois, the son of James Stephen "Jim" Mills — who, with his brother Jon, founded Medline in 1966 after their father sold the family's earlier company, Mills Hospital Supply. Charlie grew up inside the business the way other kids grow up inside a family restaurant: it was simply there, and it was expected to matter.

But the handoff was not a coronation. In 1997, Jim and Jon Mills handed the reins to three men in their 30s: Jim's son Charlie as CEO, Jon's son Andy as president, and Jon's son-in-law Jim Abrams as COO. The company they inherited did a little over $600 million in annual sales — respectable, but not the stuff of billionaires. The fortune would have to be earned from there.

Mills arrived prepared: a bachelor's degree and an MBA, both from Cornell University. He was 36 years old, running a company his father had built from scratch — with the kind of pressure that only a family business can apply.

Scaling the machine: $600 million to $25.5 billion

The numbers of the 1997–2023 run are the whole story. Under Charlie Mills' tenure as CEO, Medline:

That is roughly a 40-fold increase in revenue — and, crucially, it was profitable, cash-generating growth in a business with enormous barriers to entry. Medline is both a manufacturer (more than 20 manufacturing sites in North America) and a distributor, running the supply chain that keeps hospitals stocked with everything from surgical trays to newborn blankets. The dual model — make it and deliver it — gave Medline pricing power that pure distributors lack. For the full corporate picture, see the companies Charlie Mills owns.

The prospectus bragged, with justification, of more than 50 consecutive years of annual sales growth — a streak that survived recessions, a pandemic, and a leveraged buyout.

The COVID tailwind

The pandemic was Medline's stress test and its showcase. When COVID-19 hit, Medline ramped up production of bleach products, face masks, surgical gowns, disinfecting wipes, and toilet paper — the exact goods the world was desperate for. Revenue was $17.5 billion in 2020 and kept climbing through the crisis years.

Mills' low profile held even then. While other CEOs became cable-news fixtures, the Medline chief stayed in the background — though the company's role earned it recognition including the American Red Cross award for its disaster-response supply work during Hurricane Katrina and later emergencies. The pandemic years cemented Medline's reputation as critical infrastructure, which is exactly how investors came to see it by 2025.

The $34 billion buyout: selling control, keeping the upside

In June 2021, Blackstone, Carlyle Group, and Hellman & Friedman bought a majority stake in Medline in a leveraged buyout valued at about $34 billion — one of the biggest healthcare LBOs in history. For the Mills family, it was a masterstroke of timing.

The family rolled its equity into the deal instead of cashing out, remaining Medline's largest single shareholder with the entire senior management team staying in place. The $34 billion price tag established a hard valuation benchmark for the business — and when Medline went public four years later at an even richer valuation, it was the family's retained stake, not the private-equity firms' majority, that captured the headline upside.

At the time of the deal, Forbes noted that 20 to 30 family members stood to benefit from the family's equity — a reminder that this was never one man's company, even if Charlie held the biggest piece.

The IPO payday: December 2025

The final wealth event was the public listing. On December 16, 2025, Medline sold 216 million shares at $29 each, raising $6.26 billion — the largest IPO of 2025 anywhere in the world, and the biggest U.S. listing since Rivian in 2021. Shares debuted on the Nasdaq as MDLN and closed day one at $41, up about 41%.

At the IPO, Mills' net worth was estimated at $10.9 billion. Nine months later, the 2026 Forbes 400 pegged it at $11 billion — the stake now marked to market every trading day. The IPO proceeds went largely to debt repayment and equity redemptions, cleaning up the leveraged balance sheet from the 2021 buyout and leaving the public company — and its chairman's fortune — on firmer footing.

The disaster-response dividend

There is a lesser-known thread in the Medline growth story: disasters. The company supplied medical goods during Hurricane Katrina — work for which it received an American Red Cross award — and again during Hurricane Harvey and the coronavirus pandemic. Each crisis did two things at once: it stress-tested Medline's logistics at national scale, and it demonstrated to hospital systems that the company could deliver when supply chains everywhere else were breaking.

That reputation became a commercial asset. Hospitals choosing a prime vendor — the single distributor that manages most of a facility's supplies — prize reliability over price, because a stockout in an operating room is not a rounding error. Medline's disaster record, built over decades, helped lock in the long-term contracts that underpin the 50-year sales-growth streak. Competence in a crisis compounds just like revenue does.

Why the stake kept compounding

Strip away the deal headlines and the wealth engine was boring by design. Medline sells consumables — gloves, masks, gowns, trays — that hospitals reorder constantly, in a market where switching suppliers is disruptive and risky. That produces the predictable cash flows investors paid up for in the IPO: PitchBook analysts cited "operational maturity and margin visibility" as the reason the market rewarded a medical-supply company like a tech stock.

Mills' contribution was stewardship across 26 years: expanding manufacturing, building the distribution network across 100+ countries, and never breaking the 50-year sales-growth streak. He stepped up to chairman in 2023, handing day-to-day operations to CEO Jim Boyle, with the machine running at $25.5 billion in annual sales.

It is the classic family-business compounding story — except the compounding ran for six decades and the final number has eleven digits. As for what he actually takes home as a paycheck, that's a different story: see Charlie Mills' salary.

Frequently asked questions